Fatty liver disease, an emerging etiology of hepatocellular carcinoma in Argentina

Table 3 Comparative analysis between non alcoholic fatty liver disease and other than non alcoholic fatty liver disease

Variable	NAFLD n = 81 (11.4%)	Non-NAFLD n = 627 (88.6%)	P value
Age, yr (± SD)	63 ± 8	62 ± 4	0.39
Gender, male, n (%)	68 (83.9)	469 (74.9)	0.06
Non-cirrhotic liver, n (%)	7 (8.6)	62 (9.9)	0.72
Child Pugh A/B/C, n (%)	41 (50.6)/32 (39.5)/8 (9.9)	311 (49.6)/206 (32.8)/110 (17.5)	0.15
Comorbidities, n (%)	60 (74.1)	239 (38.1)	< 0.0001
Diabetes mellitus, n (%)	50 (61.7)	146 (23.3)	< 0.0001
Median AFP level, ng/mL	6.6 (4-380)	26 (5.3-332)	0.017
AFP > 1000 ng/mL, n (%)	9 (12.0)	97 (16.1)	0.34
Ascites, n (%)
Mild	17 (21.0)	127 (20.3)	0.7
Moderate-severe	10 (12.3)	99 (15.8)	0.7
Encephalopathy, n (%)
Grade I-II	18 (22.2)	119 (19.0)	0.2
Grade III-IV	3 (3.7)	7 (1.1)	0.2
Esophageal varices, n (%)	50 (63.3)	344 (55.8)	0.5
ECOG 0-2, n (%)	73 (90.1)	564 (89.9)	0.96
Median HCC number, (IQR)	1 (1-2)	1 (1-2)	0.38
Largest HCC diameter, mm (IQR)	55 ± 37	52 ± 37	0.51
Within Milan, n (%)	38 (46.9)	295 (47.0)	0.98
Bilobar involvement, n (%)	16 (19.7)	142 (22.7)	0.82
Diffuse HCC pattern, n (%)	3 (3.7)	20 (3.2)	0.82

AFP: Alpha-fetoprotein; MELD: Model for end stage liver disease; AFLD: Alcoholic fatty liver disease; Non-NAFLD: Other than NAFLD (includes all other etiologies).